Kaj Blennow

233.0k total citations · 75 hit papers
2.0k papers, 122.7k citations indexed

About

Kaj Blennow is a scholar working on Physiology, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Kaj Blennow has authored 2.0k papers receiving a total of 122.7k indexed citations (citations by other indexed papers that have themselves been cited), including 1.2k papers in Physiology, 845 papers in Psychiatry and Mental health and 478 papers in Molecular Biology. Recurrent topics in Kaj Blennow's work include Alzheimer's disease research and treatments (1.1k papers), Dementia and Cognitive Impairment Research (771 papers) and Neuroinflammation and Neurodegeneration Mechanisms (152 papers). Kaj Blennow is often cited by papers focused on Alzheimer's disease research and treatments (1.1k papers), Dementia and Cognitive Impairment Research (771 papers) and Neuroinflammation and Neurodegeneration Mechanisms (152 papers). Kaj Blennow collaborates with scholars based in Sweden, United Kingdom and United States. Kaj Blennow's co-authors include Henrik Zetterberg, Oskar Hansson, Harald Hampel, Niklas Mattsson, Ulf Andréasson, Lennart Minthon, Mony J. de Leon, Eugeen Vanmechelen, Niels Andreasen and Pia Davidsson and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Kaj Blennow

2.0k papers receiving 120.8k citations

Hit Papers

Alzheimer's disease 1995 2026 2005 2015 2006 2016 2009 2017 2016 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Alzheimer's disease
    2006 2.5k citations Kaj Blennow, Henrik Zetterberg et al. profile →
  2. Alzheimer's disease
    2016 2.4k citations Kaj Blennow, Giovanni B. Frisoni et al. profile →
  3. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
    2009 1.6k citations Ronald C. Petersen, Kaj Blennow et al. profile →
  4. Gut microbiome alterations in Alzheimer’s disease
    2017 1.5k citations Sterling C. Johnson, Henrik Zetterberg et al. profile →
  5. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
    2016 1.4k citations Ulf Andréasson, Kaj Blennow et al. profile →
  6. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
    2010 1.4k citations Kaj Blennow, Henrik Zetterberg et al. profile →
  7. Neurofilaments as biomarkers in neurological disorders
    2018 1.3k citations Kaj Blennow, Henrik Zetterberg et al. profile →
  8. Alzheimer's disease
    2015 1.3k citations Kaj Blennow et al. profile →
  9. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
    2006 1.3k citations Oskar Hansson, Henrik Zetterberg et al. profile →
  10. Clearance systems in the brain—implications for Alzheimer disease
    2015 1.3k citations Kaj Blennow, Henrik Zetterberg et al. profile →
  11. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
    2016 1.2k citations Clifford R. Jack, Kaj Blennow et al. Neurology profile →
  12. The Amyloid-β Pathway in Alzheimer’s Disease
    2021 1.1k citations Kaj Blennow et al. profile →
  13. CSF markers for incipient Alzheimer's disease
    2003 977 citations Kaj Blennow et al. profile →
  14. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis
    2017 819 citations Kaj Blennow, Henrik Zetterberg et al. profile →
  15. Neurofilament light chain as a biomarker in neurological disorders
    2019 811 citations Kaj Blennow, Henrik Zetterberg et al. profile →
  16. Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia
    2020 765 citations Niklas Mattsson, Sebastian Palmqvist et al. profile →
  17. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
    2017 698 citations Niklas Mattsson, Ulf Andréasson et al. profile →
  18. Biomarkers for Alzheimer's disease: current status and prospects for the future
    2018 643 citations Kaj Blennow, Henrik Zetterberg profile →
  19. tau protein in cerebrospinal fluid
    1995 636 citations Kaj Blennow et al. profile →
  20. An 18-Year Follow-up of Overweight and Risk of Alzheimer Disease
    2003 616 citations Kaj Blennow, Ingmar Skoog et al. profile →
  21. Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group
    2021 598 citations Kaj Blennow et al. profile →
  22. Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial
    2008 586 citations Kaj Blennow, Henrik Zetterberg et al. profile →
  23. Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity
    2017 576 citations Sebastian Palmqvist, Niklas Mattsson et al. Nature Communications profile →
  24. Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF
    1999 563 citations Kaj Blennow et al. Neurology profile →
  25. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa
    2016 543 citations Jens Kühle, Ulf Andréasson et al. Clinical Chemistry and Laboratory Medicine (CCLM) profile →
  26. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
    2010 536 citations Kaj Blennow et al. profile →
  27. The Neuropathology and Neurobiology of Traumatic Brain Injury
    2012 512 citations Kaj Blennow, Henrik Zetterberg et al. profile →
  28. CSF biomarkers of Alzheimer's disease concord with amyloid‐β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts
    2018 485 citations Oskar Hansson, Erik Stomrud et al. Alzheimer s & Dementia profile →
  29. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease
    2019 470 citations Niklas Mattsson, Nicholas Cullen et al. profile →
  30. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives
    2010 469 citations Henrik Zetterberg, Kaj Blennow et al. profile →
  31. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic
    2018 464 citations Henrik Zetterberg, Kaj Blennow et al. profile →
  32. Plasma β-amyloid in Alzheimer’s disease and vascular disease
    2016 447 citations Shorena Janelidze, Erik Stomrud et al. profile →
  33. Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood
    2013 446 citations Henrik Zetterberg, Kaj Blennow et al. profile →
  34. CSF and blood biomarkers for Parkinson's disease
    2019 439 citations Oskar Hansson, Kaj Blennow et al. profile →
  35. Traumatic brain injuries
    2016 428 citations Kaj Blennow, Henrik Zetterberg et al. profile →
  36. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
    2017 411 citations Kaj Blennow et al. Alzheimer s Research & Therapy profile →
  37. Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology
    2021 390 citations Nicholas J. Ashton, Thomas K. Karikari et al. profile →
  38. Plasma tau in Alzheimer disease
    2016 378 citations Niklas Mattsson, Henrik Zetterberg et al. Neurology profile →
  39. Current state of Alzheimer’s fluid biomarkers
    2018 375 citations Tobias Bittner, Michelle M. Mielke et al. profile →
  40. Blood-based NfL
    2017 356 citations Oskar Hansson, Shorena Janelidze et al. Neurology profile →
  41. Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study
    2015 356 citations Ulf Andréasson, Niklas Norgren et al. profile →
  42. Amyloid biomarkers in Alzheimer's disease
    2015 353 citations Kaj Blennow, Niklas Mattsson et al. profile →
  43. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression
    2015 347 citations Henrik Zetterberg, Niklas Mattsson et al. profile →
  44. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
    2017 325 citations Henrik Zetterberg, Markus Axelsson et al. Neurology profile →
  45. Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures
    2021 324 citations Sebastian Palmqvist, Nicholas Cullen et al. profile →
  46. CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
    2016 321 citations Henrik Zetterberg, Niklas Mattsson et al. profile →
  47. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia
    2016 319 citations Niklas Norgren, Ulf Andréasson et al. Neurology profile →
  48. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
    2021 310 citations Niklas Mattsson, Sebastian Palmqvist et al. Brain profile →
  49. Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status
    2019 299 citations Sebastian Palmqvist, Shorena Janelidze et al. profile →
  50. The probabilistic model of Alzheimer disease: the amyloid hypothesis revised
    2021 290 citations Kaj Blennow et al. profile →
  51. Traumatic Brain Injury and Alzheimer's Disease: The Cerebrovascular Link
    2018 282 citations Henrik Zetterberg, Kaj Blennow et al. profile →
  52. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease
    2021 276 citations Henrik Zetterberg, Kaj Blennow et al. profile →
  53. Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
    2021 267 citations Shorena Janelidze, Henrik Zetterberg et al. profile →
  54. Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports
    2017 250 citations Henrik Zetterberg, Kaj Blennow et al. Neurology profile →
  55. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
    2022 242 citations Shorena Janelidze, Nicholas J. Ashton et al. Brain profile →
  56. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
    2019 230 citations Sebastian Palmqvist, Erik Stomrud et al. profile →
  57. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative
    2020 218 citations Thomas K. Karikari, Andréa Lessa Benedet et al. profile →
  58. Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease
    2020 217 citations Niklas Mattsson, Henrik Zetterberg et al. profile →
  59. The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease
    2020 208 citations Henrik Zetterberg, Kaj Blennow et al. Alzheimer s Research & Therapy profile →
  60. Developing the ATX(N) classification for use across the Alzheimer disease continuum
    2021 205 citations Kaj Blennow, Clifford R. Jack et al. profile →
  61. Blood biomarkers for Alzheimer’s disease in clinical practice and trials
    2023 196 citations Oskar Hansson, Kaj Blennow et al. profile →
  62. Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
    2021 190 citations Shorena Janelidze, Henrik Zetterberg et al. Alzheimer s Research & Therapy profile →
  63. Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
    2022 170 citations Thomas K. Karikari, Nicholas J. Ashton et al. profile →
  64. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers
    2023 150 citations Niklas Mattsson, Nicholas J. Ashton et al. profile →
  65. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes
    2021 146 citations Michelle M. Mielke, Andreas Jeromin et al. profile →
  66. Plasma biomarkers for Alzheimer’s Disease in relation to neuropathology and cognitive change
    2022 134 citations Nicholas J. Ashton, Kaj Blennow et al. profile →
  67. Brain-derived tau: a novel blood-based biomarker for Alzheimer’s disease-type neurodegeneration
    2022 134 citations Nicholas J. Ashton, Henrik Zetterberg et al. Brain profile →
  68. Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance
    2022 127 citations Nicholas Cullen, Henrik Zetterberg et al. Alzheimer s & Dementia profile →
  69. Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape
    2023 121 citations Kaj Blennow et al. profile →
  70. Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
    2023 120 citations Wagner S. Brum, Henrik Zetterberg et al. profile →
  71. Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5–90 years
    2022 111 citations Ulf Andréasson, Johan Gobom et al. Brain Communications profile →
  72. Postoperative delirium and changes in the blood–brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study
    2022 106 citations Jennifer Taylor, Cameron Casey et al. British Journal of Anaesthesia profile →
  73. A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases
    2023 101 citations Wagner S. Brum, Nicholas Cullen et al. profile →
  74. Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
    2023 92 citations Nicholas J. Ashton, Henrik Zetterberg et al. profile →
  75. Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment
    2024 42 citations Shorena Janelidze, Sebastian Palmqvist et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kaj Blennow Sweden 158 65.7k 41.3k 33.4k 24.3k 22.0k 2.0k 122.7k
Henrik Zetterberg Sweden 135 46.4k 0.7× 28.5k 0.7× 26.3k 0.8× 22.4k 0.9× 17.0k 0.8× 2.0k 96.1k
Dennis W. Dickson United States 153 48.5k 0.7× 22.4k 0.5× 25.2k 0.8× 40.0k 1.6× 23.9k 1.1× 1.3k 103.6k
Bradley T. Hyman United States 156 60.6k 0.9× 24.2k 0.6× 32.6k 1.0× 14.8k 0.6× 21.1k 1.0× 730 114.1k
John Q. Trojanowski United States 193 69.9k 1.1× 26.6k 0.6× 46.3k 1.4× 59.9k 2.5× 29.4k 1.3× 1.1k 151.7k
David M. Holtzman United States 166 53.8k 0.8× 20.7k 0.5× 27.2k 0.8× 8.5k 0.4× 23.7k 1.1× 580 99.8k
Ronald C. Petersen United States 157 51.4k 0.8× 61.2k 1.5× 12.8k 0.4× 17.2k 0.7× 18.2k 0.8× 1.1k 117.0k
Philip Scheltens Netherlands 137 36.4k 0.6× 43.9k 1.1× 10.6k 0.3× 13.0k 0.5× 18.2k 0.8× 1.2k 100.6k
David S. Knopman United States 142 40.8k 0.6× 47.4k 1.1× 9.3k 0.3× 14.2k 0.6× 14.8k 0.7× 1.0k 94.0k
Clifford R. Jack United States 152 46.2k 0.7× 53.7k 1.3× 11.3k 0.3× 13.7k 0.6× 16.1k 0.7× 1.2k 105.5k
Heiko Braak Germany 107 32.3k 0.5× 14.4k 0.3× 14.3k 0.4× 26.6k 1.1× 13.8k 0.6× 362 68.5k

Countries citing papers authored by Kaj Blennow

Since Specialization
Citations

This map shows the geographic impact of Kaj Blennow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kaj Blennow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kaj Blennow more than expected).

Fields of papers citing papers by Kaj Blennow

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kaj Blennow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kaj Blennow. The network helps show where Kaj Blennow may publish in the future.

Co-authorship network of co-authors of Kaj Blennow

This figure shows the co-authorship network connecting the top 25 collaborators of Kaj Blennow. A scholar is included among the top collaborators of Kaj Blennow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kaj Blennow. Kaj Blennow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Axelsson, Markus, Henrik Zetterberg, Kaj Blennow, et al.. (2025). Ion concentrations in CSF and serum are differentially and precisely regulated. Brain Communications. 7(3). fcaf201–fcaf201.
2.
Zettergren, Anna, Nazib M. Seidu, Jenna Najar, et al.. (2024). Polygenic scores for longevity and cognitive performance are associated with predicted brain age in 70-year-olds from the general population.. SHILAP Revista de lepidopterología. 6. 100306–100306.
3.
Vontell, Regina, Kaj Blennow, Henrik Zetterberg, et al.. (2024). Association of region‐specific hippocampal reduction of neurogranin with inflammasome proteins in post mortem brains of Alzheimer's disease. Alzheimer s & Dementia Translational Research & Clinical Interventions. 10(1). e12444–e12444. 2 indexed citations
4.
Brum, Wagner S., Nicholas Cullen, Joseph Therriault, et al.. (2024). A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings. Nature Communications. 15(1). 2311–2311. 15 indexed citations
5.
Lewczuk, Piotr, Johannes Kornhuber, Thomas K. Karikari, et al.. (2024). Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression. Alzheimer s Research & Therapy. 16(1). 165–165. 4 indexed citations
6.
Johnson, Sterling C., Marc Suárez‐Calvet, Ivonne Suridjan, et al.. (2023). Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit. Alzheimer s Research & Therapy. 15(1). 25–25. 10 indexed citations
7.
Einvik, Gunnar, Truls Michael Leegaard, Trygve Tjade, et al.. (2023). Prevalence and Characteristics Associated With Post–COVID-19 Condition Among Nonhospitalized Adolescents and Young Adults. JAMA Network Open. 6(3). e235763–e235763. 59 indexed citations
8.
García‐Ayllón, María‐Salud, et al.. (2023). Levels of nicastrin species are increased in Alzheimer’s disease cerebrospinal fluid. Alzheimer s & Dementia. 19(S24). 2 indexed citations
9.
Sánchez‐Benavides, Gonzalo, Marta Milà‐Alomà, Mahnaz Shekari, et al.. (2023). The associations between glial biomarkers and cognitive changes in individuals at risk of Alzheimer’s disease. Alzheimer s & Dementia. 19(S24). 1 indexed citations
10.
Andréasson, Ulf, Johan Gobom, Vincent Delatour, et al.. (2023). Assessing the commutability of candidate reference materials for the harmonization of neurofilament light measurements in blood. Clinical Chemistry and Laboratory Medicine (CCLM). 61(7). 1245–1254. 21 indexed citations
11.
Seidu, Nazib M., Silke Kern, Simona Sacuiu, et al.. (2023). Associations between cerebrospinal fluid biomarkers and brain regions of relevance for very early Alzheimer’s disease processes. Alzheimer s & Dementia. 19(S2).
12.
Payne, Thomas, Jennifer Taylor, Cameron Casey, et al.. (2023). Prospective analysis of plasma amyloid beta and postoperative delirium in the Interventions for Postoperative Delirium: Biomarker-3 study. British Journal of Anaesthesia. 130(5). 546–556. 9 indexed citations
13.
Gregory, Sarah, Kaj Blennow, Natalie Homer, Craig Ritchie, & Graciela Muñiz‐Terrera. (2022). Self‐reported diabetes is associated with allocentric spatial processing in the European Prevention of Alzheimer's Dementia Longitudinal Cohort Study. European Journal of Neuroscience. 56(10). 5917–5930. 3 indexed citations
14.
Jónsson, Kristján, Henrik Zetterberg, Kaj Blennow, et al.. (2022). Serum biomarkers of brain injury after uncomplicated cardiac surgery: Secondary analysis from a randomized trial. Acta Anaesthesiologica Scandinavica. 66(4). 447–453. 20 indexed citations
15.
Mielke, Michelle M., Jeremy A. Syrjanen, Kaj Blennow, et al.. (2019). Plasma and CSF neurofilament light. Neurology. 93(3). 188 indexed citations
16.
Casey, Cameron, Heidi Lindroth, Rosaleena Mohanty, et al.. (2019). Postoperative delirium is associated with increased plasma neurofilament light. Brain. 143(1). 47–54. 108 indexed citations
17.
Fjell, Anders M., Donatas Sederevičius, Markus H. Sneve, et al.. (2019). Self-reported Sleep Problems Related to Amyloid Deposition in Cortical Regions with High HOMER1 Gene Expression. Cerebral Cortex. 30(4). 2144–2156. 13 indexed citations
18.
Hansson, Oskar, Shorena Janelidze, Sara Hall, et al.. (2017). Blood-based NfL. Neurology. 88(10). 930–937. 356 indexed citations breakdown →
19.
Csajbok, L. Z., Karin Nylén, Martin Öst, et al.. (2015). Apolipoprotein Epolymorphism in aneurysmal subarachnoid haemorrhage in West Sweden. Acta Neurologica Scandinavica. 133(6). 466–474. 13 indexed citations
20.
Hansson, Oskar, et al.. (2006). Erratum: Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study (Lancet Neurology (2006) 5 (228-34)). UCL Discovery (University College London).

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Henrik Zetterberg Breakdown of academic impact, for papers by Dennis W. Dickson Breakdown of academic impact, for papers by Bradley T. Hyman Breakdown of academic impact, for papers by John Q. Trojanowski Breakdown of academic impact, for papers by David M. Holtzman Breakdown of academic impact, for papers by Ronald C. Petersen Breakdown of academic impact, for papers by Philip Scheltens Breakdown of academic impact, for papers by David S. Knopman Breakdown of academic impact, for papers by Clifford R. Jack Breakdown of academic impact, for papers by Heiko Braak
Rankless by CCL
2026